Lipoprotein(a), Cardiovascular Events, and Aortic Stenosis in Routine Care and Implications for Lipoprotein(a)-Lowering Trials

Importance: In the Lp(a)HORIZON trial, pelacarsen lowered lipoprotein(a) [Lp(a)] by 78% at 12 months without reducing major adverse cardiovascular events (MACE). The neutral result raises the question of whether the cardiovascular risk associated with elevated Lp(a) in routine-care is sufficiently large to yield detectable clinical benefit in ongoing clinical trials. Objective: To quantify the association of Lp(a) with recurrent MACE and aortic valve outcomes in routine care, and to explore the implications of these associations for treatment-benefit scenarios in completed and ongoing Lp(a)-lowering trials. Design, Setting, and Participants: The study used a federated analysis of deidentified electronic health records across participating US academic medical centers. The primary retrospective cohort study analyzed adults aged 18 to 80 years with at least one Lp(a) measurement in routine care and documentation of a prior myocardial infarction, ischemic stroke, or symptomatic peripheral artery disease as of January 1, 2017 or later. Patients were followed for up to 5 years after meeting all inclusion criteria. Exposure: Baseline Lp(a), categorized as high (at least 150 nmol/L or 70 mg/dL) or low (less than 75 nmol/L or 30 mg/dL), and assessed continuously, including analyses stratified by baseline low-density lipoprotein cholesterol (LDL-C) level. Main Outcomes and Measures: Major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, ischemic stroke, or urgent coronary revascularization, and aortic stenosis or valve replacement, with hazard ratios (HRs) derived from adjusted Cox models. Results: Among 13,894 eligible patients, 13,865 contributed follow-up to outcome analyses. MACE occurred in 412 of 3,138 patients with high and 972 of 8,200 with low Lp(a) (5-year cumulative incidence, 20.1% vs 18.3%). The adjusted HR was 1.11 (95% CI, 0.98–1.25) after adjustment for age, sex, race, ethnicity, calendar year of entry, prior care, diagnosis frequency, and type and timing of the qualifying event. There was no consistent evidence of effect modification by LDL-C. In contrast, high Lp(a) was associated with aortic stenosis or valve replacement (HR, 1.62; 95% CI, 1.11–2.36). Under the assumption that pharmacological Lp(a) lowering modifies the risk represented by the observational association, a model-based analysis yielded an illustrative HR of 0.95 (95% CI, 0.89–1.02) for the magnitude of Lp(a) reduction achieved in Lp(a)HORIZON. This estimate was compatible with the reported trial HR of 1.02 and represented a smaller benefit than the trial was powered to detect. Using trial-aligned routine-care cohorts, we then projected the treatment effects for ongoing phase 3 trials of olpasiran and lepodisiran, two Lp(a) lowering agents, based on the approximately 95% reduction in Lp(a) reported in their corresponding phase 2 trials. Under three different assumptions about the timing of clinical benefit, the modeled treatment HRs ranged from 0.94 to 0.98 for OCEAN(a)-Outcomes and 0.89 to 0.97 for ACCLAIM-Lp(a). Conclusions and Relevance: In this multicenter routine-care cohort, elevated Lp(a) showed a modest and statistically insignificant association with recurrent MACE, in contrast to a stronger association with aortic stenosis or valve replacement. Modeled projections based on the observed associations suggested that ongoing trials may not be powered to detect the estimated cardiovascular benefits of Lp(a) reduction. However, these projections do not establish the treatment effects of olpasiran or lepodisiran. The findings highlight the importance of trial population, treatment duration, and clinical endpoint selection, while supporting prospective evaluation of Lp(a)-lowering therapies for aortic valve disease.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-18
DOI
https://doi.org/10.20944/preprints202611.1888.v1
Primary Topic
Lipoproteins and Cardiovascular Health
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Lipoprotein(a), Cardiovascular Events, and Aortic Stenosis in Routine Care and Implications for Lipoprotein(a)-Lowering Trials

Marcelo Montorzi, AJ Venkatakrishnan, Venky Soundararajan, C. Michael Gibson et al.
Preprints.org
Lipoproteins and Cardiovascular Health
preprint

Lipoprotein(a), Cardiovascular Events, and Aortic Stenosis in Routine Care and Implications for Lipoprotein(a)-Lowering Trials

Marcelo Montorzi, AJ Venkatakrishnan, Venky Soundararajan, C. Michael Gibson, Praveen Kumar-M
preprint en

Abstract

Importance: In the Lp(a)HORIZON trial, pelacarsen lowered lipoprotein(a) [Lp(a)] by 78% at 12 months without reducing major adverse cardiovascular events (MACE). The neutral result raises the question of whether the cardiovascular risk associated with elevated Lp(a) in routine-care is sufficiently large to yield detectable clinical benefit in ongoing clinical trials. Objective: To quantify the association of Lp(a) with recurrent MACE and aortic valve outcomes in routine care, and to explore the implications of these associations for treatment-benefit scenarios in completed and ongoing Lp(a)-lowering trials. Design, Setting, and Participants: The study used a federated analysis of deidentified electronic health records across participating US academic medical centers. The primary retrospective cohort study analyzed adults aged 18 to 80 years with at least one Lp(a) measurement in routine care and documentation of a prior myocardial infarction, ischemic stroke, or symptomatic peripheral artery disease as of January 1, 2017 or later. Patients were followed for up to 5 years after meeting all inclusion criteria. Exposure: Baseline Lp(a), categorized as high (at least 150 nmol/L or 70 mg/dL) or low (less than 75 nmol/L or 30 mg/dL), and assessed continuously, including analyses stratified by baseline low-density lipoprotein cholesterol (LDL-C) level. Main Outcomes and Measures: Major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, ischemic stroke, or urgent coronary revascularization, and aortic stenosis or valve replacement, with hazard ratios (HRs) derived from adjusted Cox models. Results: Among 13,894 eligible patients, 13,865 contributed follow-up to outcome analyses. MACE occurred in 412 of 3,138 patients with high and 972 of 8,200 with low Lp(a) (5-year cumulative incidence, 20.1% vs 18.3%). The adjusted HR was 1.11 (95% CI, 0.98–1.25) after adjustment for age, sex, race, ethnicity, calendar year of entry, prior care, diagnosis frequency, and type and timing of the qualifying event. There was no consistent evidence of effect modification by LDL-C. In contrast, high Lp(a) was associated with aortic stenosis or valve replacement (HR, 1.62; 95% CI, 1.11–2.36). Under the assumption that pharmacological Lp(a) lowering modifies the risk represented by the observational association, a model-based analysis yielded an illustrative HR of 0.95 (95% CI, 0.89–1.02) for the magnitude of Lp(a) reduction achieved in Lp(a)HORIZON. This estimate was compatible with the reported trial HR of 1.02 and represented a smaller benefit than the trial was powered to detect. Using trial-aligned routine-care cohorts, we then projected the treatment effects for ongoing phase 3 trials of olpasiran and lepodisiran, two Lp(a) lowering agents, based on the approximately 95% reduction in Lp(a) reported in their corresponding phase 2 trials. Under three different assumptions about the timing of clinical benefit, the modeled treatment HRs ranged from 0.94 to 0.98 for OCEAN(a)-Outcomes and 0.89 to 0.97 for ACCLAIM-Lp(a). Conclusions and Relevance: In this multicenter routine-care cohort, elevated Lp(a) showed a modest and statistically insignificant association with recurrent MACE, in contrast to a stronger association with aortic stenosis or valve replacement. Modeled projections based on the observed associations suggested that ongoing trials may not be powered to detect the estimated cardiovascular benefits of Lp(a) reduction. However, these projections do not establish the treatment effects of olpasiran or lepodisiran. The findings highlight the importance of trial population, treatment duration, and clinical endpoint selection, while supporting prospective evaluation of Lp(a)-lowering therapies for aortic valve disease.

Preprints.org
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon